Publications by authors named "Moataz M Reda"
HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines.
View Article and Find Full Text PDFArticle Synopsis
- Fibrotic diseases like scleroderma are associated with oxidative stress and increased pro-fibrotic gene activity, specifically involving NADPH oxidase 4 (NOX4) and heat shock protein 47 (HSP47).
- Researchers developed a nanoparticle platform that effectively delivers siRNA targeting HSP47 while also providing antioxidant effects to reduce NOX4 levels in a cell model of fibrosis.
- In studies with a mouse model of scleroderma, intradermal delivery of these nanoparticles successfully reduced HSP47 expression and other pro-fibrotic markers, improving overall skin condition.
delivery of siRNAs designed to inhibit genes important in cancer and other diseases continues to be an important biomedical goal. We now describe a new nanoparticle construct that has been engineered for efficient delivery of siRNA to tumors. The construct is comprised of a 47-nm mesoporous silica nanoparticle (MSNP) core coated with a cross-linked PEI-PEG copolymer, carrying siRNA against the HER2 oncogene, and coupled to the anti-HER2 monoclonal antibody (trastuzumab).
View Article and Find Full Text PDF